TITLE

The Synthetic CD4 Exocyclic CDR3.AME(82-89) Inhibits NF-kappaB Nuclear Translocation, HIV-1 Promoter Activation, and Viral Gene Expression

AUTHOR(S)
Roland, Joachim; Berezov, Alan; Greene, Mark I.; Murali, Ramachandran; Piatier-Tonneau, Dominique; Devaux, Christian; Briant, Laurence
PUB. DATE
November 1999
SOURCE
DNA & Cell Biology;Nov99, Vol. 18 Issue 11, p819
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We have previously shown that the synthetic aromatically modified exocyclic (AME) analog (CDR3.AME(82-89), derived from the CDR3 (residues 82-89) region of CD4 domain 1, inhibits replication of human immunodeficiency virus type 1 (HIV-1) in infected cells. In this work, we investigated the mechanism by which this inhibition is achieved. Although cells exposed to HIV-1 and treated with the CDR3.AME(82-89) peptide did not release viral particles for more than a week and kept surface expression of CD4, viral DNA was found in those cells 24 h after virus exposure, indicating that the CDR3.AME(82-89) analog does not prevent virus entry. However, virus transcription remained extremely low in infected cells, as demonstrated by the study of spliced HIV-1 mRNA in cultures treated with CDR3.AME(82-89) 72 h postinfection. Finally, the CDR3.AME(82-89) peptide was found to be a potent inhibitor of HIV-1 promoter activity and nuclear factor-kappaB translocation, indicating that the antiviral property of this peptide is, at least in part, linked with the ability of the molecule to prevent HIV-1 transcription.
ACCESSION #
6778154

 

Related Articles

  • Peptides Inhibit HIV Infection.  // PharmaGenomics;Mar/Apr2003, Vol. 3 Issue 3, p14 

    Presents information on the study entitled 'Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.' Function of Tat peptides; Benefits of using the residue cylo Q; Views of Alan Boyd from Ark Therapeutics on the study.

  • See a pocket, block it. Moore, John P.; Dragic, Tatjana // Nature;10/21/1999, Vol. 401 Issue 6755, p759 

    Discusses a discovery that a cavity formed in the HIV-1 gp41 transmembrane glycoprotein can accommodate small, circular D-peptides that could prevent HIV-1 from fusing with and entering human cells. Block to production of T cells in the immunodeficiencies of AIDS; Prevention of the necessary...

  • HIV locked out. Boyce, Nell // New Scientist;11/07/98, Vol. 160 Issue 2159, p24 

    Reports on the design of the synthetic peptide drug T-20 by researchers in order to block the entrance of HIV users to enter cells in the body. Information T-20; Comments from Michael Kilby of the University of Alabama at Birmingham regarding the first test carried out on the drug; Amount of...

  • Driving In Vitro Selection of Anti-HIV-1 TAR Aptamers by Magnesium Concentration and Temperature. Darfeuille, F.; Sekkai, D.; Dausse, E.; Kolb, G.; Yurchenko, L.; Boiziau, C.; Toulme, J.-J. // Combinatorial Chemistry & High Throughput Screening;Jun2002, Vol. 5 Issue 4, p313 

    In vitro selection with either DNA or RNA libraries was performed against the TAR RNA element of HIV-1. The role of the selection conditions on the outcome of the selection was evaluated by varying the magnesium concentration and the temperature. The selection stringency was demonstrated to...

  • Human Immunodeficiency Virus Type 1 Subtype E Envelope Recombinant Peptides Containing Naturally Immunogenic Epitopes. Chan, Sui-Yuan; Vithayasai, Vicharn; Vithayasai, Prakong; Essex, Max; Lee, Tun-Hou // Journal of Infectious Diseases;8/1/2000, Vol. 182 Issue 2 

    Analyzes the human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes. Reaction of five recombinant peptides; Presence of immunogenic epitopes in the V2 region; Location of continuous epitopes in analogous regions of the envelope.

  • Insects Antiviral and Anticancer Peptides: New Leads for the Future? Slocinska, Malgorzata; Marciniak, Pawel; Rosinski, Grzegorz // Protein & Peptide Letters;Jul2008, Vol. 15 Issue 6, p578 

    Insect produce wide range of protein and peptides as a first fast defense line against pathogen infection. These agents act in different ways including insect immune system activation or by direct impact on the target tumor cells or viruses. It has been shown that some of the insect peptides...

  • Keeping HIV out. Konforti, Boyana // Nature Structural Biology;Nov99, Vol. 6 Issue 11, p1004 

    Examines the efforts towards the discovery of reagents that block HIV entry into the cell. Background on HIV-1; Chimeric version used as a target to screen for compounds that bind to the hydrophobic pocket; Advantage of D-peptides.

  • Peptide Inhibition of HIV-1: Current Status and Future Potential. Kaushik-Basu, Neerja; Basu, Amartya; Harris, Dylan // BioDrugs;2008, Vol. 22 Issue 3, p161 

    More than 2 decades of intensive research has focused on defining replication mechanisms of HIV type 1 (HIV-1), the etiologic agent of AIDS. The delineation of strategies for combating this viral infection has yielded many innovative approaches toward this end. HIV-1 is a lentivirus in the...

  • Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Pornillos, Owen; Alam, Steven L.; Davis, Darrell R.; Sundquist, Wesley I. // Nature Structural Biology;Nov2002, Vol. 9 Issue 11, p812 

    The structural proteins of HIV and Ebola display PTAP peptide motifs (termed 'late domains') that recruit the human protein Tsg101 to facilitate virus budding. Here we present the solution structure of the UEV (ubiquitin E2 variant) binding domain of Tsg101 in complex with a PTAP peptide that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics